These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 19798490)

  • 1. Population pharmacokinetics of intravenous ondansetron in oncology and surgical patients aged 1-48 months.
    Mondick JT; Johnson BM; Haberer LJ; Sale ME; Adamson PC; Coté CJ; Croop JM; Russo MW; Barrett JS; Hoke JF
    Eur J Clin Pharmacol; 2010 Jan; 66(1):77-86. PubMed ID: 19798490
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Granisetron vs ondansetron: is it a question of duration of 5-HT3 receptor blockade?
    Blower P; Aapro M
    Br J Cancer; 2002 May; 86(10):1662-3; author reply 1664. PubMed ID: 12085221
    [No Abstract]   [Full Text] [Related]  

  • 3. Randomized, double-blind, crossover, placebo-controlled trial of intravenous ondansetron for the prevention of intrathecal chemotherapy-induced vomiting in children.
    Parker RI; Prakash D; Mahan RA; Giugliano DM; Atlas MP
    J Pediatr Hematol Oncol; 2001 Dec; 23(9):578-81. PubMed ID: 11902300
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Granisetron is equivalent to ondansetron for prophylaxis of chemotherapy-induced nausea and vomiting: results of a meta-analysis of randomized controlled trials.
    del Giglio A; Soares HP; Caparroz C; Castro PC
    Cancer; 2000 Dec; 89(11):2301-8. PubMed ID: 11147601
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nurses' perceptions of antiemetic effectiveness.
    Rhodes VA; McDaniel RW; Simms SG; Johnson M
    Oncol Nurs Forum; 1995 Sep; 22(8):1243-52. PubMed ID: 8532549
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Extrapolation of Adult Efficacy to Pediatric Patients With Chemotherapy-Induced Nausea and Vomiting.
    Momper JD; Heinrichs MT; Krudys K; Griebel D; Kumar S; Kim I; Mehrotra N; Mulberg AE; Garimella N; Nelson R; Reaman G; Sinha V; Yao L; Zineh I; Burckart G; Sachs H; Mulugeta Y
    J Clin Pharmacol; 2020 Jun; 60(6):775-784. PubMed ID: 31967340
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Double-blind, randomized comparison of the antiemetic efficacy of intravenous dolasetron mesylate and intravenous ondansetron in the prevention of acute cisplatin-induced emesis in patients with cancer. Dolasetron Comparative Chemotherapy-induced Emesis Prevention Group.
    Hesketh P; Navari R; Grote T; Gralla R; Hainsworth J; Kris M; Anthony L; Khojasteh A; Tapazoglou E; Benedict C; Hahne W
    J Clin Oncol; 1996 Aug; 14(8):2242-9. PubMed ID: 8708713
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Results of a compassionate-use program using intravenous ondansetron to prevent nausea and vomiting in patients receiving emetogenic cancer chemotherapy.
    Berry WR; House KW; Lee JT; Plagge PB; Meshad MW; Grapski R
    Semin Oncol; 1992 Dec; 19(6 Suppl 15):33-7. PubMed ID: 1485180
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety of ondansetron loading doses in children with cancer.
    Hasler SB; Hirt A; Ridolfi Luethy A; Leibundgut KK; Ammann RA
    Support Care Cancer; 2008 May; 16(5):469-75. PubMed ID: 17940810
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics of the 5HT3 receptor antagonist tropisetron in children.
    Gaedicke G; Erttmann R; Henze G; Hartmann W; Drechsler S; Grass P; Faerber L; Kutz K
    Pediatr Hematol Oncol; 1996; 13(5):405-16. PubMed ID: 10897812
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ondansetron and tropisetron in the control of nausea and vomiting in children receiving combined cancer chemotherapy.
    Stiakaki E; Savvas S; Lydaki E; Bolonaki I; Kouvidi E; Dimitriou H; Kambourakis A; Kalmanti M
    Pediatr Hematol Oncol; 1999; 16(2):101-8. PubMed ID: 10100270
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Palonosetron versus ondansetron for prevention of chemotherapy-induced nausea and vomiting in paediatric patients with cancer receiving moderately or highly emetogenic chemotherapy: a randomised, phase 3, double-blind, double-dummy, non-inferiority study.
    Kovács G; Wachtel AE; Basharova EV; Spinelli T; Nicolas P; Kabickova E
    Lancet Oncol; 2016 Mar; 17(3):332-344. PubMed ID: 26795844
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of granisetron, ondansetron and tropisetron for control of vomiting and nausea induced by cisplatin.
    Oge A; Alkiş N; Oge O; Kartum A
    J Chemother; 2000 Feb; 12(1):105-8. PubMed ID: 10768522
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of ondansetron on emesis in the first 24 hours after craniotomy in children.
    Furst SR; Sullivan LJ; Soriano SG; McDermott JS; Adelson PD; Rockoff MA
    Anesth Analg; 1996 Aug; 83(2):325-8. PubMed ID: 8694313
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy, safety and feasibility of fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting in pediatric patients receiving moderately and highly emetogenic chemotherapy - results of a non-interventional observation study.
    Willier S; Cabanillas Stanchi KM; von Have M; Binder V; Blaeschke F; Feucht J; Feuchtinger T; Döring M
    BMC Cancer; 2019 Nov; 19(1):1118. PubMed ID: 31730451
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intravenous dolasetron and ondansetron in prevention of postoperative nausea and vomiting: a multicenter, double-blind, placebo-controlled study.
    Korttila K; Clergue F; Leeser J; Feiss P; Olthoff D; Payeur-Michel C; Wessel P; Nave S; Hahne W; Brown R
    Acta Anaesthesiol Scand; 1997 Aug; 41(7):914-22. PubMed ID: 9265937
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of healthcare resource use between patients receiving ondansetron or palonosetron as prophylaxis for chemotherapy-induced nausea and vomiting.
    Yeh YC; McDonnell A; Klinger E; Fowler B; Matta L; Voit D; Reddy P
    J Oncol Pharm Pract; 2011 Sep; 17(3):179-85. PubMed ID: 20452991
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A randomized, double-blind comparison of ondansetron versus placebo for prevention of nausea and vomiting after infratentorial craniotomy.
    Fabling JM; Gan TJ; El-Moalem HE; Warner DS; Borel CO
    J Neurosurg Anesthesiol; 2002 Apr; 14(2):102-7. PubMed ID: 11907389
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ondansetron versus granisetron in the prevention of chemotherapy induced nausea and vomiting in children with acute lymphoblastic leukemia.
    Siddique R; Hafiz MG; Rokeya B; Jamal CY; Islam A
    Mymensingh Med J; 2011 Oct; 20(4):680-8. PubMed ID: 22081189
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An increased loading dose of ondansetron: a north european, double-blind randomised study in children, comparing 5 mg/m2 with 10 mg/m2.
    Brock P; Brichard B; Rechnitzer C; Langeveld NE; Lanning M; Söderhäll S; Laurent C
    Eur J Cancer; 1996 Sep; 32A(10):1744-8. PubMed ID: 8983284
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.